Kanaph Therapeutics scores $21m Series B
Kanaph Therapeutics, a South Korea-based biotech company in oncology, auto-immune, and eye diseases with large molecules and small molecules, has raised $21 million in Series B funding.
Kanaph Therapeutics, a South Korea-based biotech company in oncology, auto-immune, and eye diseases with large molecules and small molecules, has raised $21 million in Series B funding.
Copyright PEI Media
Not for publication, email or dissemination